RU2019140298A - Комбинация, ее применение и способы лечения с использованием указанной комбинации - Google Patents
Комбинация, ее применение и способы лечения с использованием указанной комбинации Download PDFInfo
- Publication number
- RU2019140298A RU2019140298A RU2019140298A RU2019140298A RU2019140298A RU 2019140298 A RU2019140298 A RU 2019140298A RU 2019140298 A RU2019140298 A RU 2019140298A RU 2019140298 A RU2019140298 A RU 2019140298A RU 2019140298 A RU2019140298 A RU 2019140298A
- Authority
- RU
- Russia
- Prior art keywords
- sodium
- dolutegravir
- rilpivirine hydrochloride
- layer
- starch glycolate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 8
- 229960004481 rilpivirine hydrochloride Drugs 0.000 claims 8
- KZVVGZKAVZUACK-BJILWQEISA-N rilpivirine hydrochloride Chemical compound Cl.CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 KZVVGZKAVZUACK-BJILWQEISA-N 0.000 claims 8
- 229940079832 sodium starch glycolate Drugs 0.000 claims 6
- 229920003109 sodium starch glycolate Polymers 0.000 claims 6
- 239000008109 sodium starch glycolate Substances 0.000 claims 6
- 229960001976 dolutegravir sodium Drugs 0.000 claims 5
- UGWJRRXTMKRYNK-VSLILLSYSA-M dolutegravir sodium Chemical compound [Na+].C([C@@H]1OCC[C@H](N1C(=O)C1=C([O-])C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F UGWJRRXTMKRYNK-VSLILLSYSA-M 0.000 claims 5
- 239000004615 ingredient Substances 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 235000010355 mannitol Nutrition 0.000 claims 4
- 239000008213 purified water Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 229960002542 dolutegravir Drugs 0.000 claims 3
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- 229920003081 Povidone K 30 Polymers 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 229960001021 lactose monohydrate Drugs 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229940069328 povidone Drugs 0.000 claims 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Многослойная таблетка для лечения ВИЧ-инфекции, содержащая
а) долутегравир натрия; и
б) гидрохлорид рилпивирина,
где долутегравир натрия и гидрохлорид рилпивирина присутствуют в отдельных слоях.
2. Таблетка по п. 1, где указанная двухслойная таблетка содержит примерно 50 мг долутегравира натрия, в эквиваленте свободной кислоты, и примерно 25 мг гидрохлорида рилпивирина, в эквиваленте свободного основания.
3. Таблетка по п. 1, дополнительно содержащая оболочку.
4. Таблетка по п. 1, где долутегравир натрия присутствует в первом слое, содержащем
и гидрохлорид рилпивирина присутствует во втором слое, содержащем
микрокристаллическая целлюлоза
5. Двухслойная таблетка для лечения ВИЧ инфекции, содержащая первый слой, содержащий долутегравир натрия; и второй слой, содержащий гидрохлорид рилпивирина; где указанная двухслойная таблетка содержит примерно 50 мг эквивалента свободной кислоты долутегравира натрия, и примерно 25 мг эквивалента свободного основания гидрохлорида рилпивирина; и где указанный первый слой и указанный второй слой непосредственно контактируют друг с другом; где первый слой содержит
и второй слой содержит
6. Способ лечения ВИЧ-инфекции у пациента, включающий введение указанному пациенту таблетки по любому из пп. 1-5.
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527169P | 2017-06-30 | 2017-06-30 | |
| US62/527,169 | 2017-06-30 | ||
| US201762535290P | 2017-07-21 | 2017-07-21 | |
| US62/535,290 | 2017-07-21 | ||
| GBGB1717131.5A GB201717131D0 (en) | 2017-10-18 | 2017-10-18 | Novel formulation |
| GB1717131.5 | 2017-10-18 | ||
| US201762589576P | 2017-11-22 | 2017-11-22 | |
| GBGB1719377.2A GB201719377D0 (en) | 2017-11-22 | 2017-11-22 | Novel formulation |
| US62/589,576 | 2017-11-22 | ||
| GB1719377.2 | 2017-11-22 | ||
| GB1806490.7 | 2018-04-20 | ||
| GBGB1806490.7A GB201806490D0 (en) | 2018-04-20 | 2018-04-20 | Novel formulation |
| PCT/IB2018/054769 WO2019003150A2 (en) | 2017-06-30 | 2018-06-27 | ASSOCIATION, USES AND THERAPEUTIC DIAGRAMS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019140298A3 RU2019140298A3 (ru) | 2021-07-30 |
| RU2019140298A true RU2019140298A (ru) | 2021-07-30 |
| RU2755710C2 RU2755710C2 (ru) | 2021-09-20 |
Family
ID=64742801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019140298A RU2755710C2 (ru) | 2017-06-30 | 2018-06-27 | Комбинация, ее применение и способы лечения с использованием указанной комбинации |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12011506B2 (ru) |
| EP (1) | EP3645003A4 (ru) |
| JP (1) | JP7287906B2 (ru) |
| KR (1) | KR102722927B1 (ru) |
| CN (1) | CN110958883A (ru) |
| AU (1) | AU2018291076B2 (ru) |
| BR (1) | BR112019027915A2 (ru) |
| CA (1) | CA3067147A1 (ru) |
| RU (1) | RU2755710C2 (ru) |
| TW (1) | TWI830703B (ru) |
| WO (1) | WO2019003150A2 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7287906B2 (ja) | 2017-06-30 | 2023-06-06 | ヴィーブ ヘルスケア カンパニー | 組み合わせ並びにその使用及びそれによる治療 |
| MA56449A (fr) * | 2019-07-03 | 2022-05-11 | Janssen Sciences Ireland Unlimited Co | Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine |
| CN116270647B (zh) * | 2023-03-14 | 2025-06-20 | 山东省农业科学院家禽研究所（山东省无特定病原鸡研究中心） | 利匹韦林在制备抗h1n1亚型猪流感病毒药物中的应用 |
| WO2025014434A1 (en) * | 2023-07-10 | 2025-01-16 | Humanis Saglik Anonim Sirketi | Dolutegravir composition with improved dissolution profile |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| ES2371442T7 (es) * | 2004-09-02 | 2022-05-12 | Janssen Pharmaceutica Nv | Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo |
| WO2009062285A1 (en) | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| WO2010011812A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| EP3210603A1 (en) | 2008-12-11 | 2017-08-30 | Shionogi & Co., Ltd | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
| MA34397B1 (fr) | 2010-07-02 | 2013-07-03 | Gilead Sciences Inc | Dérivés d'acide napht-2-ylacétique dans le traitement du sida |
| WO2012003498A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| ES2524408T5 (es) | 2010-11-19 | 2022-04-25 | Gilead Sciences Inc | Composiciones terapéuticas que comprenden rilpivirina HCl y tenofovir disoproxil fumarato |
| WO2012145728A1 (en) | 2011-04-21 | 2012-10-26 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
| PT2729448E (pt) | 2011-07-06 | 2015-12-02 | Gilead Sciences Inc | Compostos para o tratamento de vih |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| PL2742051T3 (pl) | 2011-09-14 | 2017-06-30 | Mapi Pharma Limited | Amorficzna postać soli sodowej dolutegrawiru |
| WO2013091096A1 (en) | 2011-12-20 | 2013-06-27 | Boehringer Ingelheim International Gmbh | Condensed triclyclic compounds as inhibitors of hiv replication |
| EP3070081B1 (en) | 2012-04-20 | 2018-02-28 | Gilead Sciences, Inc. | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection |
| BR112015006558A2 (pt) * | 2012-10-23 | 2017-07-04 | Cipla Ltd | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar doenças causadas por retrovírus |
| DK3067358T3 (da) | 2012-12-21 | 2019-11-04 | Gilead Sciences Inc | Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse |
| SG11201504982PA (en) | 2012-12-27 | 2015-07-30 | Japan Tobacco Inc | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR |
| US9573965B2 (en) | 2013-02-19 | 2017-02-21 | Aurobindo Pharma Ltd | Process for the preparation of Dolutegravir |
| WO2014184553A1 (en) * | 2013-05-15 | 2014-11-20 | Cipla Limited | Pharmaceutical antiretroviral compositions |
| EP3033084A1 (en) | 2013-08-14 | 2016-06-22 | ratiopharm GmbH | Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir |
| WO2015059466A1 (en) | 2013-10-25 | 2015-04-30 | Cipla Limited | Pharmaceutical compositions comprising efavirenz |
| US10087193B2 (en) * | 2014-02-07 | 2018-10-02 | Mylan Laboratories Limited | Crystalline forms of dolutegravir sodium |
| IN2014MU00916A (ru) * | 2014-03-20 | 2015-09-25 | Cipla Ltd | |
| WO2016016279A1 (en) * | 2014-07-29 | 2016-02-04 | Lek Pharmaceuticals D.D. | Novel hydrates of dolutegravir sodium |
| WO2016036759A1 (en) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir |
| JP7287906B2 (ja) | 2017-06-30 | 2023-06-06 | ヴィーブ ヘルスケア カンパニー | 組み合わせ並びにその使用及びそれによる治療 |
-
2018
- 2018-06-27 JP JP2019572713A patent/JP7287906B2/ja active Active
- 2018-06-27 WO PCT/IB2018/054769 patent/WO2019003150A2/en not_active Ceased
- 2018-06-27 CN CN201880044074.1A patent/CN110958883A/zh active Pending
- 2018-06-27 CA CA3067147A patent/CA3067147A1/en active Pending
- 2018-06-27 EP EP18823998.2A patent/EP3645003A4/en active Pending
- 2018-06-27 KR KR1020207002640A patent/KR102722927B1/ko active Active
- 2018-06-27 AU AU2018291076A patent/AU2018291076B2/en active Active
- 2018-06-27 BR BR112019027915-6A patent/BR112019027915A2/pt not_active Application Discontinuation
- 2018-06-27 RU RU2019140298A patent/RU2755710C2/ru active
- 2018-06-27 US US16/621,309 patent/US12011506B2/en active Active
- 2018-06-28 TW TW107122227A patent/TWI830703B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018291076B2 (en) | 2021-01-21 |
| AU2018291076A1 (en) | 2020-01-23 |
| US20200113838A1 (en) | 2020-04-16 |
| JP2020525520A (ja) | 2020-08-27 |
| RU2019140298A3 (ru) | 2021-07-30 |
| KR102722927B1 (ko) | 2024-10-28 |
| BR112019027915A2 (pt) | 2020-07-14 |
| CA3067147A1 (en) | 2019-01-03 |
| WO2019003150A2 (en) | 2019-01-03 |
| WO2019003150A3 (en) | 2019-02-21 |
| TW201919586A (zh) | 2019-06-01 |
| EP3645003A2 (en) | 2020-05-06 |
| RU2755710C2 (ru) | 2021-09-20 |
| CN110958883A (zh) | 2020-04-03 |
| TWI830703B (zh) | 2024-02-01 |
| KR20200024259A (ko) | 2020-03-06 |
| JP7287906B2 (ja) | 2023-06-06 |
| EP3645003A4 (en) | 2021-03-10 |
| US12011506B2 (en) | 2024-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019140298A (ru) | Комбинация, ее применение и способы лечения с использованием указанной комбинации | |
| JP2017057230A5 (ru) | ||
| FI2498756T4 (fi) | Neratinibimaleaatin tablettiformulaatiot | |
| JP2015131853A5 (ru) | ||
| ES2574836T3 (es) | Formulación de liberación prolongada de nevirapina | |
| ME01980B (me) | Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat | |
| JP2006516570A5 (ru) | ||
| KR101526553B1 (ko) | 제미글립틴 및 메트포르민을 포함하는 복합 제제 및 이의 제조방법 | |
| JP2020511419A5 (ru) | ||
| JP2004525940A5 (ru) | ||
| JP2018530566A5 (ru) | ||
| WO2016075617A1 (en) | Fixed dose pharmaceutical formulations of analgesic and anti-spasmodic drugs | |
| KR20120089787A (ko) | 염산레르카니디핀 및 발사르탄을 포함하는 복합 제제 및 이의 제조방법 | |
| RU2677649C2 (ru) | Фармацевтические композиции монтелукаста и левоцетиризина | |
| RU2007125596A (ru) | Комбинированный противотуберкулезный препарат | |
| RU2018128416A (ru) | Способ получения фармацевтической композиции, включающей производное хинолина или его соль | |
| RU2010131342A (ru) | Фармацевтическая композиция (варианты) для профилактики и лечения заболеваний нервной системы и способ ее изготовления | |
| RU2019139712A (ru) | Фармацевтическая композиция на основе миглустата N-бутил-1,5-дидезокси-1,5-имино-D-глюцита | |
| KR20130025459A (ko) | 경구투여용 서방성 다층정제 | |
| IL312036A (en) | Dosage forms comprising a plasma kallikrein inhibitor | |
| RU2022107184A (ru) | Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями | |
| RU2011128758A (ru) | Фармацевтическая противотуберкулезная комбинированная композиция | |
| RU2018103603A (ru) | Анальгезирующий, жаропонижающий, противовоспалительный препарат | |
| RU2004123357A (ru) | Фармацевтическая композиция на основе ноопепта | |
| HK40027621A (en) | Stable thiamine containing pharmaceutical formulations |